BioventusBVS +2.47%69 Net Margin % is 2.36% as of Mar. 2026. GuruFocus rates BVS with a GF Score™ of 69/100 and a GF Value™ of $6.79 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Bioventus ranks better than 57.89% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Bioventus's Net Income for the
three
months ended in Mar. 2026 was $3.1 Mil. Bioventus's Revenue for the
three
months ended in Mar. 2026 was $132.1 Mil. Therefore, Bioventus's net margin for the quarter that ended in Mar. 2026 was 2.36%.
The historical rank and industry rank for Bioventus's Net Margin % or its related term are showing as below:
BVS'
s Net Margin % Range Over the Past 10 Years
Min: -30.99 Med: -4.57 Max: 5.11
Current: 4.94
BVS's Net Margin % is ranked better than 57.89% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.09
vs BVS: 4.94
Bioventus (NAS:BVS) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Bioventus Net Margin % Related Terms
Bioventus Net Margin % Historical Data
* Premium members only.
The historical data trend for Bioventus's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Bioventus's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioventus Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bioventus's Net Margin % distribution charts can be found below:
* The bar in red indicates where Bioventus's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioventus (BVS) has a Net Margin % of 2.36% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Bioventus and its competitors. According to the industry distribution chart, Bioventus ranks #344 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 42.1%.
Is Bioventus' Net Margin % too high?
Bioventus' current Net Margin % is 2.36%. The Medical Devices & Instruments industry median Net Margin % is 2.09. Bioventus' value of 2.36% is 12.9% above this industry median. Based on the distribution chart, Bioventus ranks #344 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bioventus has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bioventus' Net Margin % compare to NPCE and TCMD?
According to the Medical Devices & Instruments industry distribution chart, Bioventus ranks #344 out of 817 companies for Net Margin %. This puts Bioventus in the upper half of its industry. The industry median Net Margin % is 2.09. Bioventus' value of 2.36% is 12.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.09, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioventus's current Net Margin % of 2.36% is 12.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Bioventus and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioventus's current Net Margin % is 2.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioventus stock overvalued right now?
Based on GuruFocus' analysis, Bioventus (BVS) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.79, compared to a current price of $9.73 — trading 43.3% above its estimated fair value. The current Net Margin % is 2.36% and 12.9% above the Medical Devices & Instruments industry median of 2.09. Bioventus' overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Bioventus (BVS), the current Net Margin % is 2.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioventus (BVS) Overvalued in 2026?
Based on GuruFocus' analysis, Bioventus stock appears to be overvalued.
The current stock price of $9.73 is trading 43.3% above its estimated GF Value™ of $6.79.
GuruFocus considers Bioventus to be Significantly Overvalued.
Key valuation signals for BVS:
Net Margin %: 2.36%
GF Value™: $6.79 vs. price of $9.73 (43.3% above fair value)
Industry Position: 12.9% above the Medical Devices & Instruments median (#344 of 817)
No single metric tells the full story. See the BVS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
69GF Score
Get the complete analysis for BVS
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BVS has been successfully added to your 
